Multiparametric magnetic resonance imaging is a diagnostic tool for prostate cancer with limited data on prognostic use. We sought to determine whether multiparametric magnetic resonance could predict aggressive prostate cancer features.
We retrospectively analyzed the records of 206 patients who underwent radical prostatectomy between 2013 and 2017. All patients had available RNA expression data on the final pathology specimen obtained from a location corresponding to a lesion location on multiparametric magnetic resonance imaging. The association between the PIRADS™ (Prostate Imaging Reporting and Data System) score and adverse pathology features were analyzed. We also performed differential transcriptomic analysis between the PIRADS groups. Factors associated with adverse pathology were analyzed using a multivariable logistic regression model.
Lesion size (p = 0.03), PIRADS score (p = 0.02) and extraprostatic extension (p = 0.01) associated significantly with the Decipher® score. Multivariable analysis showed that the PIRADS score (referent PIRADS 3, OR 8.1, 95% CI 1.2-57.5, p = 0.04), the Gleason Grade Group (referent 3, OR 5.6, 95% CI 1.5-21.1, p = 0.01) and prostate specific antigen (OR 1.103, 95% CI 1.011-1.203) were risk factors for adverse pathology findings. The difference between PIRADS 4 and 5 did not reach significance (OR 1.9, 95% CI 0.8-4.5, p = 0.12). However, the PI3K-AKT-mTOR, WNT-β and E2F signaling pathways were more active in PIRADS 5 than in PIRADS 4 cases.
The PIRADS score is associated with adverse pathology results, increased metastatic risk and differential genomic pathway activation.
The Journal of urology. 2018 Jul 03 [Epub]
Alp Tuna Beksac, Shivaram Cumarasamy, Ugo Falagario, Paige Xu, Mandeep Takhar, Mohamed Alshalalfa, Akriti Gupta, Sonya Prasad, Alberto Martini, Hari Thulasidass, Richa Rai, Mark Berger, Stefanie Hectors, Jennifer Jordan, Elai Davicioni, Sujit Nair, Kenneth Haines, Sara Lewis, Ardeshir Rastinehad, Kamlesh Yadav, Isuru Jayaratna, Bachir Taouli, Ashutosh Tewari
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York., GenomeDx Biosciences Inc., Vancouver, British Columbia, Canada., Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York., Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York., Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: .